Figure 1

Fig. 1

Scheme 1. Modification of SBL mutants with Chiral Auxiliaries.

SBL SH
$$H_3C-S-R$$
 SBL S R

1a - i Diastereomeric Enzyme $R = (R)$ or (S) modifier

$$R = S$$
 (R) -a $R^1 = Me$
 (R) -b $R^1 = H$
 $R = S$
 (R) -d $R^1 = H$
 (R) -e $R^1 = Ph$
 (R) -f $R^1 = Bn$

$$R = S \longrightarrow N \longrightarrow (R)-g R^1 = Ph \qquad R = S \longrightarrow N \longrightarrow (R)-i$$

$$R^1 \longrightarrow (R)-h R^1 = Bn$$

The corresponding (S) MTS ligands follow the same code scheme (i.e. (S)-a, (S)-b, (S)-d, (S)-e, (S)-f, (S)-g, (S)-h, (S)-i).

Scheme 2. Synthesis of Mandelate-based Ligands

OR OR OR (iv) OR
$$R^1$$
 (vii) SSO₂CH₃

(R)-1a R = Me (R)-1a R = Mom (R)-12 R = Mom (R)-12 R = Mom (R)-12 R = Mom (R)-14 R = H, R¹ = H (III) (V) (R)-7 R = Mom, R¹ = OH (VIIII) (R)-1b R = H

(III) (R)-4 R = H, R¹ = Me (VIII) (R)-8 R = Me, R¹ = OSO₂CH₃ (V) (R)-9 R = Mom, R¹ = OSO₂CH₃ (V) (R)-9 R = Mom, R¹ = OSO₂CH₃ (V) (R)-10 R = Me, R¹ = Br (R)-11 R = Mom, R¹ = Br

Reagents: (i) Me_2SO_4 , NaOH, H_2O , 37%; (ii) MeOH, H^+ ; (ii) MOM-CI, CH_2CI_2 , Et_3N (90% 2 steps); (iv) For (R)-3: BH_3 , THF, 82%; For (R)-5: $LiBH_4$, THF, 97%; (v) $MeSO_2CI$, CH_2CI_2 , Et_3N ; For (R)-8: 100%; (vi) LiBr, acetone; For (R)-10: 84%; For (R)-11: 78% 2 steps; (vii) $NaSSO_2CH_3$, DMF; For (R)-12: 61%; (viii) TFA, H_2O , 82%.

Scheme 3. Synthesis of Oxazolidinone-based Ligands

Reagents: (i) KOH, DMSO, Br $(CH_2)_nBr$; (ii) NaSSo₂CH₃, DMF.

Scheme 4. Synthesis of Indanol-based Ligands

Reagents: (i) triphosgene, CH₂Cl₂, Et₃N, 100%; (ii) KOH, DMSO, Br(CH₂)₃Br; (iii) NaSSO₂CH₃, DMF.

Fig. 5





Fig. 6A






Fig. 6C




Fig. 7A




Fig. 7B

Fig. 8